AMP Capital Investors Ltd lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 16.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 514,852 shares of the medical equipment provider’s stock after selling 104,301 shares during the period. AMP Capital Investors Ltd’s holdings in Boston Scientific were worth $12,764,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Truewealth LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $116,000. Icon Wealth Partners LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $117,000. Valeo Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the third quarter valued at approximately $138,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Boston Scientific during the third quarter valued at approximately $139,000. Finally, Cerebellum GP LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $126,000. Institutional investors own 91.85% of the company’s stock.
In other news, SVP David A. Pierce sold 8,763 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $27.74, for a total transaction of $243,085.62. Following the completion of the transaction, the senior vice president now owns 24,201 shares of the company’s stock, valued at $671,335.74. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael P. Phalen sold 15,835 shares of the business’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $25.25, for a total transaction of $399,833.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,276 shares of company stock valued at $4,592,464. Corporate insiders own 0.74% of the company’s stock.
BSX has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Boston Scientific from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. TheStreet lowered shares of Boston Scientific from a “b” rating to a “c+” rating in a research note on Thursday, December 7th. BMO Capital Markets reiterated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday, December 12th. Canaccord Genuity dropped their price objective on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, November 29th. One analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $31.06.
Shares of Boston Scientific Co. (NYSE:BSX) opened at $28.43 on Wednesday. The company has a current ratio of 0.68, a quick ratio of 0.49 and a debt-to-equity ratio of 0.54. Boston Scientific Co. has a 12 month low of $24.02 and a 12 month high of $29.93. The firm has a market cap of $39,090.00, a price-to-earnings ratio of 40.61, a price-to-earnings-growth ratio of 2.06 and a beta of 0.82.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The company had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. During the same quarter in the previous year, the company posted $0.30 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. equities research analysts forecast that Boston Scientific Co. will post 1.37 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/03/14/amp-capital-investors-ltd-sells-104301-shares-of-boston-scientific-co-bsx.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.